OncoMatch/Clinical Trials/NCT05472948
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Is NCT05472948 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Surufatinib and Sintilimab for adenocarcinoma of small intestine.
Treatment: Surufatinib · Sintilimab · Capecitabine — To explore the safety and efficacy of Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial. Meanwhile, Exploring the maximum tolerant dose or recommended II research dose of Surufatinib combined with a fixed dose of Sintilimab and Capecitabine using 3 + 3 dose climbing experiment.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 1–1(Restricted strenuous activity)
Prior therapy
Must have received: approved standard therapies
Subjects must have failed at least one line of prior treatment. Progression during or within 3 months following the last administration of approved standard therapies. Subjects in adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy.
Cannot have received: Surufatinib (Surufatinib)
Prior treatment with Surufatinib
Cannot have received: anti-PD-1 therapy
Previously received anti-programmed death-1 (PD-1) or its ligand (PD-L1) antibody
Cannot have received: anti-PD-L1 therapy
Previously received anti-programmed death-1 (PD-1) or its ligand (PD-L1) antibody
Cannot have received: anti-CTLA-4 therapy
anti-cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T- lymphocyte-associated Protein 4, CTLA-4) antibody
Cannot have received: other T cell costimulation or checkpoint pathway inhibitor
other drug/antibody that acts on T cell costimulation or checkpoint pathways
Lab requirements
Blood counts
adequate bone marrow function as assessed by the laboratory required by protocol
Kidney function
adequate renal function as assessed by the laboratory required by protocol
Liver function
adequate liver function as assessed by the laboratory required by protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify